Decision of the National Commission for Incorporation of Technologies was based on the high cost of these medications, which could have a significant budget impact on the long run
The National Commission for Incorporation of Technologies in SUS (Conitec) of the Ministry of Health has made a crucial decision by choosing not to include medicines based on Semaglutin and Liraglutin in the Unified Health System (SUS). These drugs, popularly known as ““They are widely used in the treatment of type 2 diabetes and obesity. The decision was based mainly at the high cost of these medications, which, according to the Commission, could have a significant long -term budget impact.
Conitec’s analysis involved two specific requests: one directed to patients with grade 2 and 3 obesity, over 45 years, with cardiovascular disease, and another for patients with obesity and type 2 diabetes. The average cost of each pen is $ 1,000, and projections indicate that in five years, the financial impact could reach $ 4.1 billion, and could reach $ 6 billion in more complex scenarios. Given this, the commission highlighted the existence of an alternative already available in the For these treatments, which is bariatric surgery.
The decision not to make these pens available in the public health system occurs at a time when the Ministry of Health announced a partnership between Fiocruz and the Pharmacist EMS for the national production of pens containing liraglutin and semaglutin. This initiative aims to meet the growing demand for these treatments in Brazil, offering, in the future, a more accessible alternative to patients who need these medications. Despite Conitec’s decision, pens will remain accessible on the private network.
*With information from Valéria Luizette
*Report produced with the aid of AI
